香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不會對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任何損失承擔任何責任。 再鼎醫藥有限公司* （於開曼群島註冊成立的有限公司） （股份代號：9688） 授出購股權及受限制股份單位 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。董事會謹此宣佈，於2025 年10月1日（美國東部時間），本公司根據2024年股權激勵計劃向1名承授人授出可認購 合共25,000股美國存託股份的購股權並向7名承授人涉及合共32,150股美國存託股份的受 限制股份單位。 授出2024年股權激勵計劃項下的購股權 本公司根據2024年股權激勵計劃條款向1名承授人授出25,000份購股權（以美國存託股 份計）。 購股權授出詳情如下： | 授出日期： | 2025年10月1日（美國東部時間） | | --- | --- | | 承授人數目： | 1 | | 承授人類型： | 本集團僱員參與者 | | 所授出購股權數目 | 25,000 | | （以美國存託股份計）： | | | 所授 ...

ZAWYA新闻网9月29日报道，阿布扎比投资局（ADIA）旗下全资子公司成为中国医疗健康领域私 募股权公司——礼来资本（GL Capital）单一资产延续基金（CV）的主投方。该基金投资的是美国制药 公司再鼎医药（SciClone Pharmaceuticals）。ADIA未披露此次投资金额，但据估计，该基金价值约2.3 亿美元。ADIA私募股权部执行董事哈马德·阿勒达赫里表示，再鼎是世界领先企业，其壮大得益于中国 医疗健康行业的长期稳定发展。早在2017年，礼来资本曾牵头以6.05亿美元完成对再鼎的私有化收购。 此次延续基金的设立，使礼来资本在继续掌控再鼎的同时，推动公司进一步拓展运营。 （原标题：阿布扎比投资局旗下公司成为礼来资本医疗健康基金主投方） ...

Core Viewpoint - The recent announcement by Trump regarding a 100% tariff on all brand-name drugs starting in October is expected to have limited impact on the Chinese innovative drug industry chain, according to research from China International Capital Corporation (CICC) [1] Group 1: Tariff Impact - The new tariff policy does not apply to generic drugs, biosimilars, and active pharmaceutical ingredients (APIs) [1] - Most Chinese innovative drugs that are exported either have production capacity built in the U.S. or are outsourced to local Contract Manufacturing Organizations (CMOs) [1] - The majority of exported products are APIs or raw herbal extracts, which are not affected by the new tariff, while the proportion of finished dosage forms exported is low [1] Group 2: Market Dynamics - The direct impact on CXO orders is limited in the short term, but changes in policy could affect the pace of factory construction by multinational corporations (MNCs) in the long term [1] - Upcoming catalysts include the ESMO conference scheduled for mid to late October and the results of medical insurance negotiations along with the first version of the commercial insurance innovative drug catalog expected to be released in October-November [1]

智通财经APP获悉，周二，再鼎医药(ZLAB.US)涨逾4%，报34.43美元。消息面上，特朗普近期宣布， 10月起对所有品牌/专利药征收100%关税，除非该制造商正在美国境内兴建生产设施。此关税政策不适 用于仿制药、生物相似药及原料药/API等中间体。交银国际认为，这对中国创新药产业链影响有限，无 需过度担忧。 交银国际表示，当前自主出海品种多在美自建产能或已将生产外包给美国本土CMO，而大部分国产创 新药出海采用BD模式；出口产品以原料药/生药原液为主，暂不受影响，制剂/成品药出口比例较低，下 游MNC客户投资建厂尚需时日，短期内对CXO订单直接冲击有限，长期来看政策变动也可能影响其建 厂节奏。后续催化剂包括：ESMO大会将于10月中下旬举行；医保谈判结果及第一版商保创新药目录将 于10-11月公布。 ...

Market Performance - The Hong Kong stock market indices experienced significant gains, with the Hang Seng Tech Index rising by 2.24%, reaching a new high for the period [1] - In September, the Hang Seng Tech Index accumulated a nearly 14% increase, while the Hang Seng Index and the National Enterprises Index rose by 7.09% and 6.79%, respectively [1][2] Sector Highlights - Major technology stocks saw collective gains, with Kuaishou leading with a rise of over 7%, followed by Alibaba and NetEase with increases of 2% [2][4] - Semiconductor stocks remained strong, with Huahong Semiconductor surging nearly 11% to set a new high [2][8] - Apple-related stocks also saw gains as Apple reportedly notified its supply chain to increase production capacity [2][9] Gold and Copper Stocks - Gold stocks rallied, with Zijin Mining International soaring over 68%, and other gold-related companies also showing strong performance [6] - Copper stocks followed suit, with China Molybdenum rising by 11.84% and Jiangxi Copper gaining over 8% [7] Biopharmaceutical Sector - The biopharmaceutical sector showed positive movement, with WuXi AppTec increasing by over 8% and other companies like Zai Lab and BeiGene also experiencing gains [12][13] Airline Industry - Airline stocks generally rose, with China Eastern Airlines up by 6.73% and both China Southern Airlines and Air China increasing by over 4% [11] - Citic Securities noted strong demand for air travel during the upcoming holidays, suggesting potential for positive performance in the sector [11] Oil and Gas Sector - Oil stocks collectively declined, with China Petroleum falling by 2.75% and other major oil companies also experiencing losses [14] - Reports indicated that OPEC+ plans to increase oil production in November, contributing to the downward pressure on oil prices [14] Gaming and Telecom Stocks - Casino and gaming stocks mostly fell, with Sands China down by 2.25% and other major gaming companies following suit [15] - Telecom stocks also saw declines, with China Telecom and China Mobile both experiencing slight drops [17] Capital Inflows - Southbound capital saw a net inflow of HKD 15.48 billion, indicating strong investor interest in the Hong Kong market [19] Future Outlook - Everbright Securities highlighted the strong overall profitability of Hong Kong stocks, particularly in sectors like internet, new consumption, and innovative pharmaceuticals, suggesting that despite recent gains, valuations remain low and long-term investment potential is high [19]

医药股表现强势，截至发稿，和铂医药-B(02142)涨8.2%，报15.71港元；再鼎医药(09688)涨6.83%，报 26.6港元；诺诚健华(09969)涨6.61%，报18.87港元；药明康德（603259）(02359)涨5.37%，报115.7港 元。 该行指出，当前自主出海品种多在美自建产能或已将生产外包给美国本土CMO，而大部分国产创新药 出海采用BD模式；出口产品以原料药/生药原液为主，暂不受影响，制剂/成品药出口比例较低，下游 MNC客户投资建厂尚需时日，短期内对CXO订单直接冲击有限，长期来看政策变动也可能影响其建厂 节奏。后续催化剂包括：ESMO大会将于10月中下旬举行；医保谈判结果及第一版商保创新药目录将于 10-11月公布。 消息面上，特朗普近期宣布，10月起对所有品牌/专利药征收100%关税，除非该制造商正在美国境内兴 建生产设施。此关税政策不适用于仿制药、生物相似药及原料药/API等中间体。交银国际认为，这对中 国创新药产业链影响有限，无需过度担忧。 ...

消息面上，特朗普近期宣布，10月起对所有品牌/专利药征收100%关税，除非该制造商正在美国境内兴 建生产设施。此关税政策不适用于仿制药、生物相似药及原料药/API等中间体。交银国际认为，这对中 国创新药产业链影响有限，无需过度担忧。 该行指出，当前自主出海品种多在美自建产能或已将生产外包给美国本土CMO，而大部分国产创新药 出海采用BD模式；出口产品以原料药/生药原液为主，暂不受影响，制剂/成品药出口比例较低，下游 MNC客户投资建厂尚需时日，短期内对CXO订单直接冲击有限，长期来看政策变动也可能影响其建厂 节奏。后续催化剂包括：ESMO大会将于10月中下旬举行；医保谈判结果及第一版商保创新药目录将于 10-11月公布。 智通财经APP获悉，医药股表现强势，截至发稿，和铂医药-B(02142)涨8.2%，报15.71港元；再鼎医药 (09688)涨6.83%，报26.6港元；诺诚健华(09969)涨6.61%，报18.87港元；药明康德(02359)涨5.37%，报 115.7港元。 ...

Core Viewpoint - The report from Shenwan Hongyuan indicates that Zai Lab (09688) is expected to achieve non-GAAP operating profit by Q4 2025, driven by the commercialization of products and localized production [1] Financial Projections - Revenue projections for Zai Lab from 2025 to 2027 are estimated at $553 million, $802 million, and $1.203 billion respectively, with net profit attributable to the parent company expected to be -$134 million, $15 million, and $173 million for the same years [1] - The target price set at HKD 35.2 implies a 39% upside potential, reflecting confidence in the company's innovative pipeline [1] Product Portfolio and Commercialization - Zai Lab is a global biopharmaceutical company in the commercialization stage, with seven products approved in China, including four oncology products and one immunology product [2] - Since the approval of its first commercial product, Niraparib, in 2019, Zai Lab has seen significant sales growth, with total revenue projected to reach $399 million in 2024, a 50% increase year-on-year [3] New Product Development - The company has submitted applications for new products, including KarXT and TF ADC, to the NMPA, with plans to submit for Bemarituzumab for 1L gastric cancer in the second half of the year [3] - Zai Lab anticipates revenue could reach $2 billion by 2028, supported by the sales of existing products and the approval of new products [3] Expansion of Indications - Efgartigimod, the first FcRn antagonist globally, has received approvals for multiple indications, with sales expected to reach $94 million in 2024, reflecting an 835% year-on-year growth [4] - The company is exploring additional indications for Efgartigimod, which could broaden its market reach across various medical fields [4] Global Pipeline Development - Zai Lab is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies, with several products showing potential for first-in-class (FIC) or best-in-class (BIC) status [5] - The company plans to initiate global pivotal studies for ZL-1310, which has shown promising clinical activity and safety [5]

Core Viewpoint - Zai Ding Pharma is expected to achieve non-GAAP operating profit by Q4 2025, driven by the commercialization of products and localized production [1] Financial Projections - Revenue projections for Zai Ding Pharma are $553 million, $802 million, and $1.203 billion for 2025, 2026, and 2027 respectively [1] - Net profit projections for the company are -$134 million, $15 million, and $173 million for 2025, 2026, and 2027 respectively [1] - The target price is set at HKD 35.2, indicating a potential upside of 39% [1] Product Portfolio and Pipeline - Zai Ding Pharma has seven products approved for sale in China, including four oncology products, one immunology product, and two infectious disease products [2] - The company has seen a 50% year-on-year revenue growth in 2024, reaching $399 million, primarily due to the sales increase of existing products [3] - New product applications have been submitted to NMPA, with expectations for further approvals in the near future [3] Key Product Developments - Efgartigimod (艾加莫德) is being explored for additional indications beyond its current approvals, with significant sales growth anticipated [4] - The product is expected to generate $94 million in domestic sales in 2024, reflecting an 835% increase [4] Global Pipeline Expansion - The company is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies [5] - ZL-1310 has received Fast Track designation from the FDA, with positive clinical data expected to be presented at the 2025 ASCO annual meeting [5] - The company plans to initiate global pivotal studies for ZL-1310 in the near future [5]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [5][11]. Core Insights - The company is positioned to reach a profitability inflection point due to its differentiated innovative pipeline and ongoing commercialization of its products [2][13]. - The company expects significant revenue growth, projecting revenues of $3.99 billion in 2024, $5.53 billion in 2025, $8.02 billion in 2026, and $12.03 billion in 2027, with a potential revenue of $2 billion by 2028 [2][5][11]. Summary by Sections Product Pipeline and Commercialization - The company has seven products approved for sale in China, including four oncology products, one immunology product, and two infectious disease products [2][27]. - The core products are experiencing strong sales growth, with a projected revenue increase of 50% year-over-year in 2024, driven by products like Weiwei Jia and Niu Zai Le [2][30]. - The company has submitted applications for new products, including KarXT and TF ADC, and anticipates further submissions for other products [2][12]. Financial Projections - The company forecasts revenues of $5.53 billion, $8.02 billion, and $12.03 billion for 2025, 2026, and 2027, respectively, with net profits expected to turn positive by 2027 [5][11]. - The report indicates that the company will achieve non-GAAP operating profit by Q4 2025, supported by local production and increasing product sales [41]. Market Position and Valuation - The company's current stock price reflects a valuation of 7 times the 2025 price-to-sales ratio, compared to an average of 18 times for comparable companies, indicating attractive valuation [11]. - The target price is set at HKD 35.2, representing a 39% upside potential from the current price [5][11]. Key Product Highlights - Efgartigimod (艾加莫德) is expected to become a leading product in the autoimmune field, with significant sales growth projected due to new indications and formulations [3][12]. - ZL-1310 (DLL3 ADC) has shown promising clinical data and is expected to enter critical global studies [4][38]. - The company is actively expanding its global pipeline, focusing on ADCs and bispecific antibodies, with multiple products in various stages of clinical development [4][38].